Serum adropin levels as a potential biomarker for predicting diabetic kidney disease progression.

Front Endocrinol (Lausanne) · 2025 · PMC11842233 · PMID 39991732

Europe PMC DOI

hedged sentences

0.0510

closest p · 1.0× alpha

0.0960

boldest claim

The sentences

borderline significantP =0.051so close (0.05 < p ≤ 0.1)

This association remained significant even after adjusting for serum creatinine at baseline (aOR 23.003, 95% CI 1.121-471.776, P =0.042), macroalbuminuria at baseline (aOR 21.968, 95% CI 1.085-444.659, P =0.044), use of SGLT2 inhibitors (aOR 23.496, 95% CI 1.208-456.928, P =0.037), and use of statins (aOR 40.208, 95% CI 1.389-1164.178, P =0.031), but the association became borderline significant after adjusting for the use of antihypertensive agents (aOR 17.968, 95% CI 0.990-326.052, P =0.051).

also in 11,409 other papers

borderline significanceP = 0.096so close (0.05 < p ≤ 0.1)

After adjusting for osmolality, GFR, UACR, use of anti-hypertensive agents and use of statins, the serum adropin level showed borderline significance (adjusted odds ratio (aOR) 1.001, 95% confidence interval (CI) 1.000-1.003, P = 0.096) between subjects with diabetes and controls. 3.3.

also in 7,017 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.